公开(公告)号：EP0499987A1

公开(公告)日：1992-08-26

申请号：EP92102532.6

申请日：1992-02-14

Applicant: ABBOTT LABORATORIES

Inventor： Summers, James B. ,  Sheppard, George S. ,  Phillips, James G. ,  Steinman, Douglas H. ,  Guinn, Denise E. ,  Carrera, George M, Jr. ,  Pireh, Daisy ,  May, Paul D. ,  Heyman, H. Robin ,  Davidsen, Steven K.

IPC: C07D417/14 ,  C07D409/14 ,  C07D413/14 ,  A61K31/44 ,  A61K31/425

CPC classification number: C07D409/14 ,  C07D417/14

Abstract: Indole compounds substituted at the 1- or 3-position by a (pyrid-3-yl)thiazolid-4-yl)alkyl-, (pyrid-3-yl)thiazolid-4-oyl)-, (pyrid-3-yl)dithiolan-4-yl)alkyl- or (pyrid-3-yl)dithiolan-4-oyl)- group are potent inhibitors of PAF and are useful in the treatment of PAF-related disorders including septic shock, respiratory distress syndrome, acute inflammation, delayed cellular immunity, parturtition, fetal lung maturation, and cellular differentiation.

Abstract translation: 通过（吡啶-3-基）噻唑烷-4-基）烷基 - ，（吡啶-3-基）噻唑烷-4-基） - （吡啶-3-基） - （吡啶-3-基） ）二硫戊环-4-基）烷基 - 或（吡啶-3-基）二硫戊环-4-基） - 是PAF的有效抑制剂，可用于治疗PAF相关疾病，包括脓毒性休克，呼吸窘迫综合征，急性 炎症，延迟的细胞免疫，分泌，胎儿肺成熟和细胞分化。

公开(公告)号：EP0405506A1

公开(公告)日：1991-01-02

申请号：EP90112261.4

申请日：1990-06-27

Applicant: ABBOTT LABORATORIES

Inventor： Chung, John Y.-L. ,  Tufano, Michael D. ,  May, Paul D. ,  Shiosaki, Kazumi ,  Nadzan, Alex M. ,  Garvey, David S. ,  Shue, Youe-Kong ,  Brodie, Mark S. ,  Holladay, Mark W.

IPC: C07K5/00 ,  A61K37/02

CPC classification number: C07K5/1016 ,  A61K38/00 ,  C07K5/0207 ,  C07K5/0808 ,  C07K5/1024

Abstract: A tetrapeptide type-B CCK receptor ligand of the formula
A-B-C-D
or a pharmaceutically acceptable salt thereof, which is useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and treatment of shock, respiratory and cardiocirculatory insufficiencies.

Abstract translation: 用于治疗中枢神经系统疾病，药物滥用，胃肠道疾病，内分泌紊乱，进食相关疾病和休克，呼吸和心脏循环治疗的ABCD的四肽B型CCK受体配体或其药学上可接受的盐 不足。